-
EP4245319
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4245319
| EP4245319 - ANTIBODY-BASED CONJUGATE FOR ENHANCING THERAPEUTIC EFFECT OF TARGETED THERAPEUTIC AGENT [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 18.08.2023 Database last updated on 31.08.2024 | |
| Former | The international publication has been made Status updated on 21.05.2022 | Most recent event Tooltip | 12.01.2024 | Change: Validation states | published on 14.02.2024 [2024/07] | 12.01.2024 | Change - extension states | published on 14.02.2024 [2024/07] | Applicant(s) | For all designated states The Catholic University of Korea Industry-Academic Cooperation Foundation Catholic Univ. of Korea Songeui Campus 222, Banpo-daero Seocho-gu Seoul / KR | [2023/38] | Inventor(s) | 01 /
NA, Kun Bucheon-si, Gyeonggi-do 14574 / KR | 02 /
KIM, Da Hye Seoul 07372 / KR | 03 /
AHN, Min Ji Seoul 08012 / KR | 04 /
PARK, Na Eun Incheon 21977 / KR | [2023/38] | Representative(s) | Plasseraud IP 104 Rue de Richelieu CS92104 75080 Paris Cedex 02 / FR | [N/P] |
| Former [2023/38] | Plasseraud IP 66, rue de la Chaussée d'Antin 75440 Paris Cedex 09 / FR | Application number, filing date | 21892337.3 | 11.11.2021 | [2023/38] | WO2021KR16438 | Priority number, date | KR20200150142 | 11.11.2020 Original published format: KR 20200150142 | KR20210122669 | 14.09.2021 Original published format: KR 20210122669 | [2023/38] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022103170 | Date: | 19.05.2022 | Language: | KO | [2022/20] | Type: | A1 Application with search report | No.: | EP4245319 | Date: | 20.09.2023 | Language: | EN | [2023/38] | Search report(s) | International search report - published on: | KR | 19.05.2022 | Classification | IPC: | A61K47/59, A61P35/00, C07K16/28, A61K39/00 | [2023/38] | CPC: |
A61P35/00 (EP,US);
A61K47/6851 (EP,US);
A61K39/00 (EP,US);
A61K41/0071 (EP,US);
A61K47/60 (EP,US);
A61K47/6803 (EP);
A61K47/6849 (EP);
A61K47/6889 (US);
C07K16/2827 (EP);
C07K16/2863 (EP);
C07K16/32 (EP);
A61K2039/505 (EP);
C07K2317/24 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/38] | Title | German: | ANTIKÖRPERBASIERTES KONJUGAT ZUR VERBESSERUNG DER THERAPEUTISCHEN WIRKUNG EINES GEZIELTEN THERAPEUTISCHEN MITTELS | [2023/38] | English: | ANTIBODY-BASED CONJUGATE FOR ENHANCING THERAPEUTIC EFFECT OF TARGETED THERAPEUTIC AGENT | [2023/38] | French: | CONJUGUÉ À BASE D'ANTICORPS POUR AMÉLIORER L'EFFET THÉRAPEUTIQUE D'UN AGENT THÉRAPEUTIQUE CIBLÉ | [2023/38] | Entry into regional phase | 01.06.2023 | Translation filed | 01.06.2023 | National basic fee paid | 01.06.2023 | Search fee paid | 01.06.2023 | Designation fee(s) paid | 01.06.2023 | Examination fee paid | Examination procedure | 01.06.2023 | Examination requested [2023/38] | Fees paid | Renewal fee | 29.11.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]KR20150131366 (ABBVIE DEUTSCHLAND [DE], et al); |